Baihui Pharmaceutical Group

Blog

16

2020-06

From Harbin Pharmaceutical to Jin Sheng Zang: Why is relentless, money-draining advertising no longer working?

2020-06-16

28

2019-05

Imported drugs are getting cheaper, while locally developed innovative medicines find themselves in an awkward situation.

Recently, a report titled "Why Has This Major Innovative Drug—Which Could Significantly Lower Prices of Imported Medicines—Still Not Been Included in National Reimbursement Programs Nine Years After Its Launch?" has sparked strong reactions within the industry. With reforms in new drug approval processes and the ongoing advancement of generic drug consistency evaluations, Chinese pharmaceutical companies are growing increasingly enthusiastic about developing innovative medicines. However, despite being domestically developed and innovative, the market performance of these drugs remains mixed—some thrive, while others struggle. For instance, China's first Class 1.1 fluoroquinolone antibacterial agent, which boasts independent intellectual property rights, has yet to be added to the national medical insurance catalog or the essential drug lists of public healthcare institutions in most regions, even after nine years on the market. Meanwhile, another Class 1 new drug developed entirely with domestic expertise…

2019-05-28

Imported drugs are getting cheaper, while locally developed innovative medicines find themselves in an awkward situation.

28

2019-05

The scope of medical insurance drug reimbursement is expanding—Which pharmaceutical companies will benefit?

On May 13, the National Healthcare Security Administration, jointly with the Ministry of Finance, issued the "Notice on Doing a Good Job in Basic Medical Insurance for Urban and Rural Residents in 2019," which clearly emphasized the need to establish and improve a unified outpatient expense management and payment mechanism for urban and rural residents' medical insurance, with a particular focus on safeguarding against the heavy financial burdens posed by common and chronic diseases. Specifically, medications prescribed for outpatient treatment of conditions such as hypertension and diabetes will now be included in the scope of medical insurance reimbursement.

2019-05-28

28

2019-05

Traditional Chinese medicine formula granules are gradually becoming mainstream, with China's traditional Chinese medicine market surpassing 7 billion yuan to claim dominance.

In recent years, the state has been encouraging the development of traditional Chinese medicine (TCM), yet at the same time, regulations on Chinese herbal injections have become increasingly stringent. As a result, it has become challenging to develop new proprietary TCM drugs, while Chinese medicinal herbs and TCM formula granules have gradually emerged as promising new avenues for industry breakthroughs. Currently, several well-established pharmaceutical companies in China—such as Kangmei Pharmaceutical, China National Medicines Corporation, Hongri Pharmaceutical, Xiangxue Pharmaceutical, and Tailong Pharmaceutical—are leading players in the market, each with significant sales volumes of either Chinese medicinal herbs or TCM formula granules. Among them, Kangmei Pharmaceutical has long been the industry leader in Chinese medicinal herbs; however, recently it has drawn considerable attention—and raised market concerns—due to allegations of "financial fraud," which has also cast doubt on the company's core business in this area. Meanwhile, China National Medicines Corporation stands out as the dominant force in the TCM formula granules market.

2019-05-28

28

2019-05

China's pharmaceutical excipient industry looks forward to higher-quality development.

May 27 — Pharmaceutical excipients play crucial roles such as shaping, serving as carriers, enhancing drug stability, improving solubility, aiding dissolution, and enabling controlled-release formulations—they are vital ingredients that can significantly impact the quality, safety, and efficacy of pharmaceutical products. Amidst current policies that encourage the development of advanced dosage forms and promote green practices in both pharmaceuticals and active pharmaceutical ingredients, fostering high-quality growth in China's pharmaceutical excipient industry has become an urgent necessity.

2019-05-28

29

2019-04

Can eating more soybeans or soy products replace soy isoflavone and vitamin E capsules?

What makes Xishilan Soy Isoflavone Vitamin E Capsules special? The Xishilan Soy Isoflavone Vitamin E Capsules (commonly known as "Xishilan Women's Vitality Supplement") are specifically designed for women and have been approved by the U.S. FDA. The soy isoflavones in these capsules are derived from high-quality, natural soybeans, carefully extracted using advanced, low-temperature supercritical extraction technology. They are further enriched with natural vitamin E—an antioxidant sourced from wheat germ—and processed into a formulation through cutting-edge manufacturing techniques. Extensive long-term observation and testing have confirmed that this product is completely free of toxic side effects. Xishilan Soy

2019-04-29

Can eating more soybeans or soy products replace soy isoflavone and vitamin E capsules?
< 123456 >

Sorry，当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry，The current column has no content!

You can view other columns or return Home